Pomegranate and its components as alternative treatment for prostate cancer

International Journal of Molecular Sciences

Volumn 15, Issue 9, 2014, Pages 14949-14966

  Wang, Lei ^a   Martins Green, Manuela ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ellagic acid; Luteolin; Metastasis; Natural products; Punicic acid

Indexed keywords

PLANT EXTRACT;

ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); HUMAN; LYTHRACEAE; MALE; METABOLISM; PHYTOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC NEOPLASMS; PUNICACEAE;

EID: 84906823753     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150914949     Document Type: Review

References (105)

1. American Cancer Society. Available online: http://www.cancer.org/ (accessed on 1 July 2014).
2. Stavridi, F.; Karapanagiotou, E.M.; Syrigos, K.N. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat. Rev. 2010, 36, 122-130
3. Chuu, C.P.; Kokontis, J.M.; Hiipakka, R.A.; Fukuchi, J.; Lin, H.P.; Lin, C.Y.; Huo, C.; Su, L.C. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J. Biomed. Sci. 2011, 18, 63
4. Hoffman-Censits, J.; Fu, M. Chemotherapy and targeted therapies: Are we making progress in castrate-resistant prostate cancer? Semin. Oncol. 2013, 40, 361-374
5. Higano, C.S.; Small, E.J.; Schellhammer, P.; Yasothan, U.; Gubernick, S.; Kirkpatrick, P.; Kantoff, P.W. Sipuleucel-T. Nat. Rev. Drug Discov. 2010, 9, 513-514
6. Sartor, O.; Pal, S.K. Abiraterone and its place in the treatment of metastatic crpc. Nat. Rev. Clin. Oncol. 2013, 10, 6-8
7. Ryan, C.J.; Smith, M.R.; de Bono, J.S.; Molina, A.; Logothetis, C.J.; de Souza, P.; Fizazi, K.; Mainwaring, P.; Piulats, J.M.; Ng, S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 2013, 368, 138-148
8. Yakes, F.M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B., et al. Cabozantinib (xl184), a novel met and vegfr2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 2011, 10, 2298-2308
9. Smith, D.C.; Smith, M.R.; Sweeney, C.; Elfiky, A.A.; Logothetis, C.; Corn, P.G.; Vogelzang, N.J.; Small, E.J.; Harzstark, A.L.; Gordon, M.S., et al. Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J. Clin. Oncol. 2013, 31, 412-419
10. Longtin, R. The pomegranate: Nature's power fruit? J. Natl. Cancer Inst. 2003, 95, 346-348
11. Langley, P. Why a pomegranate? BMJ 2000, 321, 1153-1154
12. Gil, M.I.; Tomas-Barberan, F.A.; Hess-Pierce, B.; Holcroft, D.M.; Kader, A.A. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J. Agric. Food Chem. 2000, 48, 4581-4589
13. Lansky, E.P.; Newman, R.A. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J. Ethnopharmacol. 2007, 109, 177-206
14. Kim, N.D.; Mehta, R.; Yu, W.; Neeman, I.; Livney, T.; Amichay, A.; Poirier, D.; Nicholls, P.; Kirby, A.; Jiang, W., et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res. Treat. 2002, 71, 203-217
15. Khan, N.; Afaq, F.; Mukhtar, H. Cancer chemoprevention through dietary antioxidants: Progress and promise. Antioxid. Redox Signal. 2008, 10, 475-510
16. Noda, Y.; Kaneyuki, T.; Mori, A.; Packer, L. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: Delphinidin, cyanidin, and pelargonidin. J. Agric. Food Chem. 2002, 50, 166-171
17. Albrecht, M.; Jiang, W.; Kumi-Diaka, J.; Lansky, E.P.; Gommersall, L.M.; Patel, A.; Mansel, R.E.; Neeman, I.; Geldof, A.A.; Campbell, M.J. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J. Med. Food 2004, 7, 274-283
18. Malik, A.; Afaq, F.; Sarfaraz, S.; Adhami, V.M.; Syed, D.N.; Mukhtar, H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 14813-14818
19. Sanchez, I.; Dynlacht, B.D. New insights into cyclins, cdks, and cell cycle control. Semin. Cell Dev. Biol. 2005, 16, 311-321
20. Harper, J.W.; Adami, G.R.; Wei, N.; Keyomarsi, K.; Elledge, S.J. The p21 cdk-interacting protein cip1 is a potent inhibitor of g1 cyclin-dependent kinases. Cell 1993, 75, 805-816
21. Malik, A.; Mukhtar, H. Prostate cancer prevention through pomegranate fruit. Cell Cycle 2006, 5, 371-373
22. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J., et al. An inhibitor of bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681
23. Wang, L.; Alcon, A.; Yuan, H.; Ho, J.; Li, Q.J.; Martins-Green, M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr. Biol. 2011, 3, 742-754
24. Hong, M.Y.; Seeram, N.P.; Heber, D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J. Nutr. Biochem. 2008, 19, 848-855
25. Ming, D.S.; Pham, S.; Deb, S.; Chin, M.Y.; Kharmate, G.; Adomat, H.; Beheshti, E.H.; Locke, J.; Guns, E.T. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 2014, 143c, 19-28
26. Rettig, M.B.; Heber, D.; An, J.; Seeram, N.P.; Rao, J.Y.; Liu, H.; Klatte, T.; Belldegrun, A.; Moro, A.; Henning, S.M., et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-κB-dependent mechanism. Mol. Cancer Ther. 2008, 7, 2662-2671
27. Klein, K.A.; Reiter, R.E.; Redula, J.; Moradi, H.; Zhu, X.L.; Brothman, A.R.; Lamb, D.J.; Marcelli, M.; Belldegrun, A.; Witte, O.N., et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 1997, 3, 402-408
28. McCarty, M.F.; Hejazi, J.; Rastmanesh, R. Beyond androgen deprivation: Ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer. Integr. Cancer Ther. 2014, doi:10.1177/1534735414534728
29. Adhami, V.M.; Siddiqui, I.A.; Syed, D.N.; Lall, R.K.; Mukhtar, H. Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the tramp model. Carcinogenesis 2012, 33, 644-651
30. Lansky, E.P.; Jiang, W.; Mo, H.; Bravo, L.; Froom, P.; Yu, W.; Harris, N.M.; Neeman, I.; Campbell, M.J. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Investig. New Drugs 2005, 23, 11-20
31. Honn, K.V.; Bockman, R.S.; Marnett, L.J. Prostaglandins and cancer a review of tumor initiation through tumor metastasis. Prostaglandins 1981, 21, 833-864
32. Chaudry, A.; McClinton, S.; Moffat, L.E.F.; Wahle, K.W.J. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br. J. Cancer 1991, 64, 1157-1160
33. Hyde, C.A.; Missailidis, S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int. Immunopharmacol. 2009, 9, 701-715
34. Piomelli, D. Arachidonic acid in cell signaling. Curr. Opin. Cell Biol. 1993, 5, 274-280
35. Schneider, C.; Pozzi, A. Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev. 2011, 30, 277-294
36. Khan, Z.; Khan, N.; Tiwari, R.P.; Sah, N.K.; Prasad, G.B.; Bisen, P.S. Biology of Cox-2: An application in cancer therapeutics. Curr. Drug Targets 2011, 12, 1082-1093
37. Yang, P.; Cartwright, C.A.; Li, J.; Wen, S.; Prokhorova, I.N.; Shureiqi, I.; Troncoso, P.; Navone, N.M.; Newman, R.A.; Kim, J. Arachidonic acid metabolism in human prostate cancer. Int. J. Oncol. 2012, 41, 1495-1503
38. Sheng, H.; Shao, J.; Washington, M.K.; DuBois, R.N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 2001, 276, 18075-18081
39. Ghosh, J.; Myers, C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 13182-13187
40. Patel, M.I.; Singh, J.; Niknami, M.; Kurek, C.; Yao, M.; Lu, S.; Maclean, F.; King, N.J.; Gelb, M.H.; Scott, K.F., et al. Cytosolic phospholipase A2-α: A potential therapeutic target for prostate cancer. Clin. Cancer Res. 2008, 14, 8070-8079
41. Attiga, F.A.; Fernandez, P.M.; Weeraratna, A.T.; Manyak, M.J.; Patierno, S.R. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000, 60, 4629-4637
42. Brinckerhoff, C.E.; Matrisian, L.M. Matrix metalloproteinases: A tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 2002, 3, 207-214
43. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010, 141, 52-67
44. Page-McCaw, A.; Ewald, A.J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8, 221-233
45. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17, 463-516
46. Friedl, P.; Wolf, K. Tube travel: The role of proteases in individual and collective cancer cell invasion. Cancer Res. 2008, 68, 7247-7249
47. Overall, C.M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-672
48. Nelson, A.R.; Fingleton, B.; Rothenberg, M.L.; Matrisian, L.M. Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. 2000, 18, 1135-1149
49. Hamdy, F.C.; Fadlon, E.J.; Cottam, D.; Lawry, J.; Thurrell, W.; Silcocks, P.B.; Anderson, J.B.; Williams, J.L.; Rees, R.C. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 1994, 69, 177-182
50. Hadler-Olsen, E.; Winberg, J.O.; Uhlin-Hansen, L. Matrix metalloproteinases in cancer: Their value as diagnostic and prognostic markers and therapeutic targets. Tumor Biol. 2013, 34, 2041-2051
51. Afaq, F.; Zaid, M.A.; Khan, N.; Dreher, M.; Mukhtar, H. Protective effect of pomegranate-derived products on UVB-mediated damage in human reconstituted skin. Exp. Dermatol. 2009, 18, 553-561
52. Ahmed, S.; Wang, N.; Hafeez, B.B.; Cheruvu, V.K.; Haqqi, T.M. Punica granatum l. Extract inhibits IL-1β-induced expression of matrix metalloproteinases by inhibiting the activation of map kinases and NF-κB in human chondrocytes in vitro. J. Nutr. 2005, 135, 2096-2102
53. Auvinen, P.; Tammi, R.; Parkkinen, J.; Tammi, M.; Agren, U.; Johansson, R.; Hirvikoski, P.; Eskelinen, M.; Kosma, V.M. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 2000, 156, 529-536
54. Aaltomaa, S.; Lipponen, P.; Tammi, R.; Tammi, M.; Viitanen, J.; Kankkunen, J.P.; Kosma, V.M. Strong stromal hyaluronan expression is associated with PSA recurrence in local prostate cancer. Urol. Int. 2002, 69, 266-272
55. Lipponen, P.; Aaltomaa, S.; Tammi, R.; Tammi, M.; Agren, U.; Kosma, V.M. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur. J. Cancer 2001, 37, 849-856
56. Turley, E.A. Hyaluronan and cell locomotion. Cancer Metastasis Rev. 1992, 11, 21-30
57. Toole, B.P.; Zoltan-Jones, A.; Misra, S.; Ghatak, S. Hyaluronan: A critical component of epithelial-mesenchymal and epithelial-carcinoma transitions. Cells Tissues Organs 2005, 179, 66-72
58. Turley, E.A.; Noble, P.W.; Bourguignon, L.Y.W. Signaling properties of hyaluronan receptors. J. Biol. Chem. 2002, 277, 4589-4592
59. Gust, K.M.; Hofer, M.D.; Perner, S.R.; Kim, R.; Chinnaiyan, A.M.; Varambally, S.; Moller, P.; Rinnab, L.; Rubin, M.A.; Greiner, J., et al. Rhamm (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 2009, 11, 956-963
60. Lin, S.-L.; Chang, D.; Chiang, A.; Ying, S.-Y. Androgen receptor regulates CD168 expression and signaling in prostate cancer. Carcinogenesis 2008, 29, 282-290
61. Lin, S.-L.; Chang, D.; Ying, S.-Y. Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis 2007, 28, 310-320
62. Wang, L.; Ho, J.; Glackin, C.; Martins-Green, M. Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis. Transl. Oncol. 2012, 5, 344-355
63. Roudier, M.P.; Vesselle, H.; True, L.D.; Higano, C.S.; Ott, S.M.; King, S.H.; Vessella, R.L. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results. Clin. Exp. Metastasis 2003, 20, 171-180
64. Loberg, R.D.; Gayed, B.A.; Olson, K.B.; Pienta, K.J. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J. Cell. Biochem. 2005, 96, 439-446
65. Bubendorf, L.; Schopfer, A.; Wagner, U.; Sauter, G.; Moch, H.; Willi, N.; Gasser, T.C.; Mihatsch, M.J. Metastatic patterns of prostate cancer: An autopsy study of 1589 patients. Hum. Pathol. 2000, 31, 578-583
66. Furusato, B.; Mohamed, A.; Uhlen, M.; Rhim, J.S. CXCR4 and cancer. Pathol. Int. 2010, 60, 497-505
67. Hirbe, A.C.; Morgan, E.A.; Weilbaecher, K.N. The CXCR4/SDF-1 chemokine axis: A potential therapeutic target for bone metastases? Curr. Pharm. Des. 2010, 16, 1284-1290
68. Wang, J.; Loberg, R.; Taichman, R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006, 25, 573-587
69. Taichman, R.S.; Cooper, C.; Keller, E.T.; Pienta, K.J.; Taichman, N.S.; McCauley, L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62, 1832-1837
70. Culig, Z.; Steiner, H.; Bartsch, G.; Hobisch, A. Interieukin-6 regulation of prostate cancer cell growth. J. Cell. Biochem. 2005, 95, 497-505
71. Cooper, A.M.; Khader, S.A. IL-12p40: An inherently agonistic cytokine. Trends Immunol. 2007, 28, 33-38
72. Apte, R.N.; Dotan, S.; Elkabets, M.; White, M.R.; Reich, E.; Carmi, Y.; Song, X.; Dvozkin, T.; Krelin, Y.; Voronov, E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006, 25, 387-408
73. Vaday, G.G.; Peehl, D.M.; Kadam, P.A.; Lawrence, D.M. Expression of CCL5 (rantes) and CCR5 in prostate cancer. Prostate 2006, 66, 124-134
74. Hernandez, F.; Melgarejo, P.; Tomas-Barberan, F.A.; Artes, F. Evolution of juice anthocyanins during ripening of new selected pomegranate (punica granatum) clones. Eur. Food Res. Technol. 1999, 210, 39-42
75. Van Elswijk, D.A.; Schobel, U.P.; Lansky, E.P.; Irth, H.; van der Greef, J. Rapid dereplication of estrogenic compounds in pomegranate (Punica granatum) using on-line biochemical detection coupled to mass spectrometry. Phytochemistry 2004, 65, 233-241
76. Gomez-Caravaca, A.M.; Verardo, V.; Toselli, M.; Segura-Carretero, A.; Fernandez-Gutierrez, A.; Caboni, M.F. Determination of the major phenolic compounds in pomegranate juices by HPLC-DAD-ESI-MS. J. Agric. Food Chem. 2013, 61, 5328-5337
77. Ackland, M.L.; van de Waarsenburg, S.; Jones, R. Synergistic antiproliferative action of the flavonols quercetin and kaempferol in cultured human cancer cell lines. In Vivo 2005, 19, 69-76
78. Qu, W.; Breksa, A.P., III; Pan, Z.; Ma, H. Quantitative determination of major polyphenol constituents in pomegranate products. Food Chem. 2012, 132, 1585-1591
79. Schubert, S.Y.; Lansky, E.P.; Neeman, I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J. Ethnopharmacol. 1999, 66, 11-17
80. Grossmann, M.E.; Mizuno, N.K.; Schuster, T.; Cleary, M.P. Punicic acid is an OMEGA-5 fatty acid capable of inhibiting breast cancer proliferation. Int. J. Oncol. 2010, 36, 421-426
81. Gasmi, J.; Sanderson, J.T. Growth inhibitory, antiandrogenic, and pro-apoptotic effects of punicic acid in lncap human prostate cancer cells. J. Agric. Food Chem. 2010, 58, 12149-12156
82. Seeram, N.P.; Henning, S.M.; Zhang, Y.; Suchard, M.; Li, Z.; Heber, D. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J. Nutr. 2006, 136, 2481-2485
83. Heber, D. Multitargeted therapy of cancer by ellagitannins. Cancer Lett. 2008, 269, 262-268
84. Seeram, N.P.; Aronson, W.J.; Zhang, Y.; Henning, S.M.; Moro, A.; Lee, R.-P.; Sartippour, N.; Harris, D.M.; Rettig, M.; Suchard, M.A., et al. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J. Agric. Food Chem. 2007, 55, 7732-7737
85. Sartippour, M.R.; Seeram, N.P.; Rao, J.Y.; Moro, A.; Harris, D.M.; Henning, S.M.; Firouzi, A.; Rettig, M.B.; Aronson, W.J.; Pantuck, A.J., et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int. J. Oncol. 2008, 32, 475-480
86. Castonguay, A.; Gali, H.; Perchellet, E.; Gao, X.; Boukharta, M.; Jalbert, G.; Okuda, T.; Yoshida, T.; Hatano, T.; Perchellet, J. Antitumorigenic and antipromoting activities of ellagic acid, ellagitannins and oligomeric anthocyanin and procyanidin. Int. J. Oncol. 1997, 10, 367-373
87. Narayanan, B.A.; Geoffroy, O.; Willingham, M.C.; Re, G.G.; Nixon, D.W. P53/p21 (WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett. 1999, 136, 215-221
88. Losso, J.N.; Bansode, R.R.; Trappey, A., 2nd; Bawadi, H.A.; Truax, R. In vitro anti-proliferative activities of ellagic acid. J. Nutr. Biochem. 2004, 15, 672-678
89. Vicinanza, R.; Zhang, Y.; Henning, S.M.; Heber, D. Pomegranate juice metabolites, ellagic acid and urolithin a, synergistically inhibit androgen-independent prostate cancer cell growth via distinct effects on cell cycle control and apoptosis. Evid.-Based Complement. Alternat. Med. 2013, 2013, 247-504
90. Huang, Y.T.; Hwang, J.J.; Lee, P.P.; Ke, F.C.; Huang, J.H.; Huang, C.J.; Kandaswami, C.; Middleton, E., Jr.; Lee, M.T. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in a431 cells overexpressing epidermal growth factor receptor. Br. J. Pharmacol. 1999, 128, 999-1010
91. Selvendiran, K.; Koga, H.; Ueno, T.; Yoshida, T.; Maeyama, M.; Torimura, T.; Yano, H.; Kojiro, M.; Sata, M. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: An implication for the antitumor potential of flavonoids. Cancer Res. 2006, 66, 4826-4834
92. Lim, Y.; Jeong, Y.; Tyner, A.L.; Park, J.H. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G66-G75
93. Zhou, Q.; Yan, B.; Hu, X.; Li, X.B.; Zhang, J.; Fang, J. Luteolin inhibits invasion of prostate cancer pc3 cells through E-cadherin. Mol. Cancer Ther. 2009, 8, 1684-1691
94. Perez-Moreno, M.; Jamora, C.; Fuchs, E. Sticky business: Orchestrating cellular signals at adherens junctions. Cell 2003, 112, 535-548
95. Berx, G.; van Roy, F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb. Perspect. Biol. 2009, 1, a003129
96. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442-454
97. Pratheeshkumar, P.; Son, Y.O.; Budhraja, A.; Wang, X.; Ding, S.; Wang, L.; Hitron, A.; Lee, J.C.; Kim, D.; Divya, S.P., et al. Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One 2012, 7, e52279
98. Rocha, A.; Wang, L.; Penichet, M.; Martins-Green, M. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. Breast Cancer Res. Treat. 2012, 136, 647-658
99. Mulholland, D.J.; Kobayashi, N.; Ruscetti, M.; Zhi, A.; Tran, L.M.; Huang, J.; Gleave, M.; Wu, H. Pten loss and RAS/MAPK activation cooperate to promote emt and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012, 72, 1878-1889
100. Wang, L.; Garcia, M.; Mulholland, D.; Lily, M.; Martins-Green, M. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis 2014, doi:10.1093/carcin/bgu145
101. Pantuck, A.J.; Leppert, J.T.; Zomorodian, N.; Aronson, W.; Hong, J.; Barnard, R.J.; Seeram, N.; Liker, H.; Wang, H.; Elashoff, R., et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin. Cancer Res. 2006, 12, 4018-4026
102. Paller, C.J.; Ye, X.; Wozniak, P.J.; Gillespie, B.K.; Sieber, P.R.; Greengold, R.H.; Stockton, B.R.; Hertzman, B.L.; Efros, M.D.; Roper, R.P., et al. A randomized phase II study of pomegranate extract for men with rising psa following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013, 16, 50-55
103. Freedland, S.J.; Carducci, M.A.; Kroeger, N.; Partin, A.W.; Rao, J.; Jin, Y.; Kerkoutian, S.; Wu, H.; Li, Y.; Creel, P., et al. A double-blind, randomized, neoadjuvant study of the tissue effects of pomx pills in men with prostate cancer prior to radical prostatectomy. Cancer Prev. Res. 2013, 10, 1120-1127
104. Thomas, R.; Williams, M.; Sharma, H.; Chaudry, A.; Bellamy, P. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer-The U.K. NCRN POMI-T study. Prostate Cancer Prostatic Dis. 2014, 17, 180-186
105. Adhami, V.M.; Khan, N.; Mukhtar, H. Cancer chemoprevention by pomegranate: Laboratory and clinical evidence. Nutr. Cancer 2009, 61, 811-815.